Recent Finacing
Recent Raise
Phoenix Molecular Designs develops RSK-targeted cancer therapeutics and companion diagnostics, advancing lead RSK2 inhibitor PMD-026 through IND-enabling studies with partnerships including NCI and academic centers.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at Phoenix Molecular Designs.
